Advancing Non-Opioid Pain Management for Osteoarthritis Using iPSC-Derived Nociceptor Cell Therapy Approach

Friday, November 14, 2025

9:53 AM - 10:01 AM CT

Location: Griffin Hall - Screen 03

Introduction:

Osteoarthritis (OA) affects 250 million people worldwide, with knee OA being most common [1, 2]. Chronic knee OA pain, both nociceptive and neuropathic, limits mobility, quality of life, and drives opioid-based pain medication. Non-opioid analgesics face challenges due to limited efficacy and short duration of action. Human induced pluripotent stem cells (hiPSC) offer innovative, off-the-shelf therapies for targeted, durable pain relief, representing a promising alternative for chronic pain management.

Submitting Author(s)

TP

Tea Soon Park, Ph.D.

Head of Cell Therapy
SereNeuro Therapeutics
Baltimore, Maryland, United States

Co-Author(s)

ZW

Zhuolun Poppy Wang, Ph.D.

Postdoctoral Fellow
Johns Hopkins School of Medicine, United States
WZ

Weixin Zhang, Ph.D.

Postdoctoral Fellow
Johns Hopkins School of Medicine, United States
DS

Daniel Saragnese, n/a

CEO
SereNeuro Therapeutics, United States
XD

Xinzhong Dong, Ph.D.

Professor
Johns Hopkins School of Medicine, United States
GL

Gabsang Lee, Ph.D.

Professor
Johns Hopkins School of Medicine, United States